ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,18608
0,06%
Bitcoin
99.021,15
0,71%
Brent Oil
76,45
-0,07%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Gossamer Bio Inc (GOSS)

  7. Gossamer Bio Inc (GOSS) Notícias

GOSS

Gossamer Bio (GOSS)

Gossamer Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GOSS
DataHoraFonteTítuloCódigoCompanhia
12/11/202418:40Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GOSSGossamer Bio Inc
11/11/202418:01Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
07/11/202418:03Business WireGossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
07/11/202418:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
07/11/202418:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GOSSGossamer Bio Inc
26/08/202417:01Business WireGossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024NASDAQ:GOSSGossamer Bio Inc
12/08/202417:01Business WireGossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
06/06/202422:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
14/05/202417:01Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceNASDAQ:GOSSGossamer Bio Inc
07/05/202417:01Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
06/05/202408:30Business WireGossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsNASDAQ:GOSSGossamer Bio Inc
03/05/202409:02Business WireGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineNASDAQ:GOSSGossamer Bio Inc
12/03/202408:31Business WireGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
05/03/202409:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GOSSGossamer Bio Inc
05/03/202409:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GOSSGossamer Bio Inc
05/03/202409:31Business WireGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
13/12/202318:01Business WireGossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023NASDAQ:GOSSGossamer Bio Inc
05/12/202319:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
05/12/202309:01Business WireGossamer Bio Appoints Bob Smith as Chief Commercial OfficerNASDAQ:GOSSGossamer Bio Inc
29/11/202309:01Business WireGossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
09/11/202309:31Business WireGossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
03/10/202317:08Business WireGossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical AffairsNASDAQ:GOSSGossamer Bio Inc
07/09/202308:44Business WireGossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023NASDAQ:GOSSGossamer Bio Inc
29/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GOSSGossamer Bio Inc
28/08/202317:29Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOSSGossamer Bio Inc
21/08/202317:01Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:GOSSGossamer Bio Inc
18/08/202309:41Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GOSSGossamer Bio Inc
18/08/202309:38Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:GOSSGossamer Bio Inc
17/08/202317:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:GOSSGossamer Bio Inc
08/08/202317:01Business WireGossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GOSS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
PRIO3
PETRORIO ON
BOV
BEEF3
MINERVA ON
BOV
BRAV3
Brava Energia ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados